Cortechs.ai | Lesion Change Visualization with LesionQuant 2.3

Lesion Change Visualization with LesionQuant 2.3

Did you know that the LesionQuant module offers lesion change visualization images?

Lesion change visualization is available when a current and prior LesionQuant study have been processed and are available in the system. Change values of lesions are determined by using both 3D T1 and (2D or 3D) T2 FLAIR MRIs.

Similar to a heat map, regions are color-coded to identify increasing and decreasing image intensities between the current and prior scans.

  • Cyan/Dark blue indicates decreasing intensity, which may indicate decreasing lesion activity
  • Orange/Red indicates increasing intensity, which may indicate increasing lesion activity
  • Areas with no change in intensity are not colored

Cortechs.ai | Lesion Change Visualization with LesionQuant 2.3

Reproducibility and Comparison Best Practices:
It is best practice to perform the current MRI on the same MRI scanner and series protocol as the prior MRI. If different scanners and/or protocols are used, caution should be taken when interpreting the results.

When patient data is already in the system:
If an earlier scan for the patient has been processed by LesionQuant (same software version) and is available in the system, change volume images are automatically included in the output sent to the PACS/DICOM Viewer. The PatientID must match on both time points, and the StudyInstanceUID must match on the individual T1/FLAIR pair.

When patient data is no longer in the system or there has been a change in the software version from the current scan:
To obtain the change visualization, the user must reprocess the original scan pair, then send the new scan pair for processing to receive the change analysis and volumes. The PatientID must match on both time points, and the StudyInstanceUID must match on the individual T1/FLAIR pair.

More Resources

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.
Scroll to Top